pharmos bmo capital markets focus on healthcare conference december 7 2006 nasdaq pars 2 safe harbor statement statements made in this presentation related to the business outlook and future financial performance of company prospective market penetration its drug products development commercialization s pipeline potential from acquisition vela expectations connection with any event condition or other matter are forward looking pursuant provisions securities litigation reform act 1995 such involve risks uncertainties that may cause results differ materially those set forth these for example there can be no assurance i due unforeseen medical scientific consequences often arise new drugs clinical trials candidate including cannabinor dextofisopam will have sufficiently positive enable ii management technical problems delays accompany integration two businesses realize
